Sprint Bioscience AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 0.041 million compared to SEK 0.018 million a year ago. Revenue was SEK 0.599 million compared to SEK 0.024 million a year ago. Net loss was SEK 11.73 million compared to SEK 17.91 million a year ago. Basic loss per share from continuing operations was SEK 0.17 compared to SEK 0.45 a year ago.
For the six months, sales was SEK 0.041 million compared to SEK 0.063 million a year ago. Revenue was SEK 1.61 million compared to SEK 0.078 million a year ago. Net loss was SEK 24.01 million compared to SEK 32.11 million a year ago. Basic loss per share from continuing operations was SEK 0.34 compared to SEK 0.81 a year ago.